Acumen Pharmaceuticals, Inc (ABOS) - Narx-foyda koeffitsiyenti
Bozor baholovini tasdiqlovchi hujjat sifatida Acumen Pharmaceuticals (ABOS) narxlar grafigi aktiv dinamikasini namoyish etmoqda, bunda ko'rsatkich -0.20 darajasida turibdi. Acumen Pharmaceuticals mustahkam ilmiy asosga tayangan holda, Altsgeymer kasalligiga qarshi kurashish uchun zamonaviy immunoterapiya usullarini ishlab chiqmoqda. Rahbarlar jamoasi tadqiqotlarning aniqligiga va tasdiqlangan tibbiy ma'lumotlarni to'plashga tikmoqda. Moliyaviy barqarorlik mavjud naqd pul zaxiralariga bog'liq, chunki ishlab chiqish jarayoni asosiy dori vositalari sinovlari natijalariga qarab belgilanadi.
Acumen Pharmaceuticals kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- balans bo'yicha xususiy kapital ma'lumotlari:
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning kapitalga nisbati Acumen Pharmaceuticals|ABOS - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi Acumen Pharmaceuticals, Inc|ABOS - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Acumen Pharmaceuticals, Inc.|ABOS - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli majburiyatlar Acumen Pharmaceuticals|Oraliq qoplash koeffitsiyenti acumenpharm.com
- sof foyda va baholash koeffitsiyentlari ma'lumotlari:
ABOS - Sof foyda|Prognoz qilingan kelajakdagi foyda Acumen Pharmaceuticals|ABOS - Narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori Acumen Pharmaceuticals Inc.|ABOS - Narxning foydaga va o‘sish sur’atiga nisbati|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti Acumen Pharmaceuticals, Inc.|ABOS - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) Acumen Pharmaceuticals|ABOS - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi acumenpharm.com|ABOS - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi Acumen Pharmaceuticals
Kompaniyaning umumiy tahlili:acumenpharm.com - ABOS
Kompaniya kapitali joriy operatsion foydasiz, ammo istiqbolli antitanachlar ishlanmalariga asoslangan Acumen Pharmaceuticals (ABOS) uchun ushbu koeffitsient bozorning kelajakdagi ilmiy muvaffaqiyatlarga bo'lgan kutganlarini aks ettiradi. Emitentning P/E koeffitsienti orqali vizuallashtirilgan bozor kapitalizatsiyasining sof foydaga nisbati daromadning har bir birligi uchun xarajatni o'lchaydi, bu esa investorga aktivlarning pul oqimini yaratishga bo'lgan haqiqiy qobiliyatiga nisbatan qanchalik hadda haddan tashqari baholanganligini aniqlash imkonini beradi.
Raqobatdosh kompaniyalar tahlili
P/E multiplikatori biogen.com|P/E multiplikatori NBIX|Narx-foyda koeffitsiyenti Regencell Bioscience Ltd RGC|Axsome Therapeutics Inc - Narx-foyda koeffitsiyenti|P/E multiplikatori ACADIA Corp ACAD|XENE - Narxning foydaga nisbati|vikingtherapeutics.com (VKTX) - Narx-foyda koeffitsiyenti|SUPN: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Catalyst Pharma (CPRX)|Narxning foydaga nisbati Denali Therapeutics Inc|Narx-foyda multiplikatori HRMY (Harmony Corp)|Narx-foyda koeffitsiyenti BHVN (Biohaven Ltd.)|AMLX (amylyx.com) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Trevi Therapeutics, Inc. TRVI|PRAX (Praxis Precision Medicines Inc) - Kapitalizatsiyaning sof foydaga nisbati|Anavex Corp - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati CBLL (CeriBell EEG)|PRTA: P/E multiplikatori|Alector (ALEC) - P/E multiplikatori|Narxning foydaga nisbati Annexon|OMER: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Neurogene Corp (NGNE)|Narx-foyda koeffitsiyenti AC Immune Inc ACIU|P/E multiplikatori VYGR (Voyager Therapeutics)|P/E multiplikatori neumoratx.com NMRA|Scilex - P/E multiplikatori|Tevogen Bio Holdings Inc. (TVGN) - Narx-foyda koeffitsiyenti|ACOG: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Cognition Therapeutics Inc. (CGTX)|Narx-foyda koeffitsiyenti IKT|P/E multiplikatori cassavasciences.com|Narx-foyda koeffitsiyenti ASRT (Assertio Holdings, Inc.)|Bozor narxining sof foydaga nisbati COYA|P/E multiplikatori VTGN (Vistagen)|Biznesning o‘zini qoplash muddati Ovid Therapeutics Inc (OVID)|CervoMed Inc. - P/E multiplikatori|Alterity Therapeutics (ATHE) - Narx-foyda koeffitsiyenti|CLNN: P/E multiplikatori|PepGen (PEPG) - P/E multiplikatori|Narxning foydaga nisbati Jupiter Neurosciences|Narxning foydaga nisbati RLMD|Narxning foydaga nisbati Annovis Bio, Inc. (ANVS)|Biznesning o‘zini qoplash muddati gracetx.com|P/E multiplikatori AIFF (Firefly Neuroscience)|P/E multiplikatori ANEW Medical KLTO|NeuroSense Therapeutics, Ltd. - P/E multiplikatori|RVPH: Narxning foydaga nisbati|metaviatx.com (MTVA) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati neuraxis.com (NRXS)|Narxning foydaga nisbati Helius Medical Technologies, Inc.|Passage Bio Corp (PASG) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Neuphoria Therapeutics Inc. (NEUP)|Minerva - Narx-foyda multiplikatori|P/E multiplikatori ATHA (Athira Pharma, Inc.)|addextherapeutics.com (ADXN) - Kapitalizatsiyaning foydaga nisbati|ALZN: Narx-foyda koeffitsiyenti|CYCN - P/E multiplikatori|protagenic.com (PTIX) - Narxning foydaga nisbati|Pasithea Therapeutics Corp. - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Cortigent Inc|Kapitalizatsiyaning foydaga nisbati avenuetx.com ATXI|P/E multiplikatori BCLI|P/E multiplikatori Cara Therapeutics Inc. (CARA)|P/E multiplikatori CHRO (Chromocell Therapeutics Corporation)|ELYM - Narx-foyda koeffitsiyenti|ITCI: Narx-foyda koeffitsiyenti|LBPH - P/E multiplikatori|Marinus Pharmaceuticals, Inc. (MRNS) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti NKGen Biotech Inc|NRBO (NeuroBo) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Sage Therapeutics Inc SAGE|Narxning foydaga nisbati Synaptogenix, Inc. (SNPX)|trevena.com - Narx-foyda multiplikatori|Vigil Neuroscience, Inc. - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati WENA|CERE - Narxning foydaga nisbati
